Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Lipid-lowering drug
DRUG
2 trials
Sponsors
Universidad Miguel Hernandez de Elche
, Fu Wai Hospital, Beijing, China
Conditions
Adverse Event
In-stent Restenosis
Overdose
Phase 4
Anti-inflammatory Therapy for Recurrent In-stent Restenosis
Recruiting
NCT06090890
Fu Wai Hospital, Beijing, China
In-stent Restenosis
Start: 2023-10-30
End: 2027-10-29
Target: 252
Updated: 2025-08-08
Unknown Phase
Consequences of Doing What Should Not be Done in Primary Care
Completed
NCT03482232
Universidad Miguel Hernandez de Elche
Adverse Event, Overdose
Start: 2018-10-14
End: 2020-02-10
Updated: 2020-04-03
Related Papers
Anti-inflammatory therapy for recurrent in-stent restenosis (AI-ISR): study protocol for a prospective, randomised, open-label, multicentre clinical trial.
2025-10-27
Avoidable Adverse Events Related to Ignoring the Do-Not-Do Recommendations: A Retrospective Cohort Study Conducted in the Spanish Primary Care Setting
Journal of Patient Safety
2021-04-12
23 citations
SOBRINA Spanish study—analysing the frequency, cost and adverse events associated with overuse in primary care: protocol for a retrospective cohort study
BMJ Open
2019-03-01
4 citations